Biotech Strategy Blog

JNJ acquisition of Aragon ARN-509 deals a blow to Medivation

Pieter Droppert — Mon, 17 Jun 2013 13:28:03 +0000

Johnson & Johnson (JNJ) just announced the acquisition of privately-held Aragon Pharmaceuticals and the rights to ARN-509 a second-generation androgen…

ASCO 2013 Abraxane in pancreatic cancer is a welcome new treatment option

Pieter Droppert — Fri, 07 Jun 2013 11:21:21 +0000

At ASCO 2013 Daniel D. Van Hoff, MD, Physician-In-Chief of the Translational Genomics Research Institute (TGen), presented the data for the…

AZD3514 Fails to Live up to Preclinical Promise in CRPC at ASCO 2013

Pieter Droppert — Thu, 06 Jun 2013 10:33:51 +0000

AZD3514 is a novel Selective Androgen Receptor Down-Regulating Drug (SARD) that showed early preclinical promise for the treatment of Castration-Resistant…

ASCO 2013 Pfizer joins race to develop a Herceptin biosimilar with PF-05280014

Pieter Droppert — Wed, 05 Jun 2013 17:26:32 +0000

At the 2013 Annual Meeting of the American Society of Clinical Oncology in Chicago this past weekend, my impression of…

ASCO 2013: Cancer Drug Combinations are The Future

Pieter Droppert — Mon, 03 Jun 2013 11:35:46 +0000

Chicago – At the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Charles L Sawyers, MD,…

ASCO 2013 CLL Runners and Riders in Race to Market #ASCO13

Pieter Droppert — Tue, 28 May 2013 20:15:04 +0000

THE data of the 2013 annual meeting of the American Society of Clinical Oncology (ASCO) that starts later this week…

AACR 2013 Posters offer Insights into Biotech Drug Development

Pieter Droppert — Mon, 15 Apr 2013 14:43:49 +0000

In my final post from the 2013 annual meeting of the American Association for Cancer Research (AACR), I wanted to…

AACR 2013 posters show potential new Pfizer cancer drugs

Pieter Droppert — Fri, 12 Apr 2013 15:05:11 +0000

My overriding impression of large cap Pharma R&D from the 2013 annual meeting of the American Association for Cancer Research…

AACR 2013 Cancer Scientists fail to embrace Social Media

Pieter Droppert — Thu, 11 Apr 2013 14:28:32 +0000

I will be writing in the next few days about some of the Pharma and Biotech winners and losers at…

AACR 2013 GDC-0032 a next generation PI3K Inhibitor shows early promise in breast cancer

Pieter Droppert — Mon, 08 Apr 2013 13:00:14 +0000

Genentech’s next generation PI3-kinase inhibitor, GDC-0032, was the topic of two presentations yesterday at the 2013 annual meeting of the…